The Future of Lung Cancer Precision Medicine with Dr. Andrea Mazzocchi

July 19, 2021
Kevin Kunzmann

Strategic Alliance Partnership | <b>American Lung Association</b>

The co-founder and CEO of Known Medicine dissects the art and science of how profiling biomarkers, epigenetics and the microenvironment may provide the synergy needed to revolutionize the oncologic landscape.

Lung cancer treatment is on the precipice of unheralded advancement in its field. The intersection of advanced diagnostics, targeted immunotherapy, and implementation of artificial intelligence-borne pathology has created a possibility of concise, individualized care.

Or, as many refer to it, precision medicine.

In this newest episode of Lungcast, American Lung Association (ALA) chief medical officer Al Rizzo, MD, sits down with Andrea Mazzocchi, PhD, co-founder and chief executive officer of Known Medicine, and adjunct professor at Wake Forest University.

After reviewing the ever-long beneficial teachings of Persian scientist Avicenna and his influence on modern precision medicine, Rizzo and Mazzocchi discuss the ins and outs of emerging lung cancer tools and capabilities.

Lungcast is a monthly respiratory health podcast series from the ALA, produced by HCPLive.

Subscribe or listen to Lungcast on your favorite platforms:


x